MedTrace Logo

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

NCT07673302 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-08-06

No results posted yet for this study

Summary

The aim of this study is to determine the safety and therapeutic effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on beta thalassemia patients. The main objectives of this study are:

* To determine the therapeutic efficacy of HbF inducers (combination therapy: thalidomide and hydroxyurea) on hemoglobin level and blood transfusion in beta thalassemia patients.
* To determine the safety of HbF inducers (combination therapy: thalidomide and hydroxyurea) in beta thalassemia patients
* To determine effect of HbF inducers (combination therapy: thalidomide and hydroxyurea) on quality of life of beta thalassemia patients

Conditions

Interventions

DRUG

Thalidomide

Tab Thalidomide 0.5 to 4 mg/kg orally every day for 12 months

DRUG

Hydroxy Urea

Tab Hydroxyurea 10-20 mg/kg per day for 12 months

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Fariha Sardar, MBBS, FCPS · Riphah International University, Rwp

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-20
Primary Completion
2027-06-19
Completion
2027-06-19

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673302 on ClinicalTrials.gov